Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.84 - $1.22 $37,978 - $55,158
45,212 New
45,212 $54,000
Q2 2023

Aug 14, 2023

BUY
$1.09 - $9.93 $57,672 - $525,406
52,911 Added 138.33%
91,162 $109,000
Q1 2023

May 15, 2023

BUY
$7.77 - $12.47 $170,520 - $273,666
21,946 Added 134.6%
38,251 $334,000
Q4 2022

Feb 14, 2023

BUY
$5.52 - $8.48 $90,003 - $138,266
16,305 New
16,305 $130,000

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.